Lower CVD Mortality for Metformin Versus Sulfonylureas

Share this content:
Lower CVD Mortality for Metformin Versus Sulfonylureas
Lower CVD Mortality for Metformin Versus Sulfonylureas

TUESDAY, April 19, 2016 (HealthDay News) -- Metformin is associated with reduced cardiovascular mortality compared with sulfonylureas, according to a large analysis published online April 19 in the Annals of Internal Medicine.

Shari Bolen, M.D., M.P.H., assistant professor of medicine at the Case Western Reserve University's Center for Health Care Research and Policy in Cleveland, and colleagues conducted the analysis, which included 204 studies involving 1.4 million people.

The researchers found that metformin reduced the risk of dying from heart attack and stroke by about 30 to 40 percent compared with sulfonylureas such as glibenclamide, glimepiride, glipizide, and tolbutamide.

"The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas)," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Dermatography Helps Lessen Appearance of Surgical Scars

Dermatography Helps Lessen Appearance of Surgical Scars

Pigments can restore more natural skin appearance that patients are happy with

Drug-Resistant Bacteria Live in America's Water Systems

Drug-Resistant Bacteria Live in America's Water Systems

Bacteria found in plumbing may sicken thousands each year

Deep Brain Stimulation May Improve TBI Symptoms

Deep Brain Stimulation May Improve TBI Symptoms

Deep brain stimulation appears to boost function and quality of life

is free, fast, and customized just for you!

Already a member?

Sign In Now »